GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (STU:0I3) » Definitions » Institutional Ownership

Axonics (STU:0I3) Institutional Ownership : 55.82% (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Axonics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Axonics's institutional ownership is 55.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Axonics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Axonics's Float Percentage Of Total Shares Outstanding is 88.60%.


Axonics Institutional Ownership Historical Data

The historical data trend for Axonics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Institutional Ownership Chart

Axonics Historical Data

The historical data trend for Axonics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 84.07 88.71 86.64 87.88 91.01 76.32 74.05 57.48 55.91 55.82

Axonics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Axonics (STU:0I3) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Axonics (STU:0I3) Headlines

No Headlines